A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, Among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis

Trial Profile

A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, Among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Bedaquiline (Primary) ; Delamanid (Primary) ; Dolutegravir
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Jan 2021 to 1 Jul 2020.
    • 01 Aug 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2018.
    • 25 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top